乳腺癌治疗后淋巴水肿的发生时机:患者何时风险最高
该研究纳入2005至2017年在本机构因单侧或双侧乳腺癌接受手术的2171例女性(2266条高危手臂),用周径测量法客观评估术前肢体体积,淋巴水肿定义为术后3个月以上相对手臂体积增加≥10%。中位随访4年,估计5年淋巴水肿累积发生率为13.7%;腋窝淋巴结清扫与早发型淋巴水肿相关,区域淋巴结放疗与晚发型淋巴水肿相关,淋巴水肿风险高峰时间随治疗方式不同而异。
要点
- 中位随访4年,总体估计5年淋巴水肿累积发生率为13.7%。
- 腋窝淋巴结清扫联合区域淋巴结放疗者5年淋巴水肿发生率最高,为31.2%。
- 腋窝淋巴结清扫与早发型淋巴水肿相关(HR 4.75,P < .0001),区域淋巴结放疗与晚发型淋巴水肿相关(HR 3.86,P = .0001)。
核心结论
- 淋巴水肿的发展时间过程取决于所接受的乳腺癌治疗。
- 腋窝淋巴结清扫与早发型淋巴水肿相关,区域淋巴结放疗与晚发型淋巴水肿相关。
- 这些结果可影响临床实践,以指导淋巴水肿监测策略和患者教育。
研究设计与样本
- 2005年至2017年间,本机构因单侧或双侧乳腺癌接受手术的2171例女性(2266条高危手臂)入组。
- 术前采用周径测量法客观评估肢体体积,淋巴水肿定义为术后3个月以上相对手臂体积增加≥10%。
- 采用多因素回归分析淋巴水肿相关危险因素,采用Cox比例风险模型计算淋巴水肿发生率,并计算淋巴水肿的半年风险率。
主要发现
- 中位随访4年,总体估计5年淋巴水肿累积发生率为13.7%。
- 多因素分析中与淋巴水肿显著相关的因素为术前高体重指数、腋窝淋巴结清扫和区域淋巴结放疗。
- 接受腋窝淋巴结清扫联合区域淋巴结放疗的患者5年淋巴水肿发生率最高(31.2%),其次为接受腋窝淋巴结清扫未联合区域淋巴结放疗者(24.6%)和接受前哨淋巴结活检联合区域淋巴结放疗者(12.2%)。
- 总体而言,淋巴水肿风险在术后12至30个月之间达到高峰;但时间过程随所接受的治疗不同而变化。
- 早发型淋巴水肿(术后<12个月)与腋窝淋巴结清扫相关(HR 4.75;P < .0001),但与区域淋巴结放疗不相关(HR 1.21;P = .55);晚发型淋巴水肿(术后>12个月)与区域淋巴结放疗相关(HR 3.86;P = .0001),与腋窝淋巴结清扫相关程度较低(HR 1.86;P = .029)。
临床怎么用
- 作者指出,这些结果可影响临床实践,以指导淋巴水肿监测策略和患者教育。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of the study was to determine when the risk of lymphedema is highest after treatment of breast cancer and which factors influence the time course of lymphedema development. METHODS AND MATERIALS: Between 2005 and 2017, 2171 women (with 2266 at-risk arms) who received surgery for unilateral or bilateral breast cancer at our institution were enrolled. Perometry was used to objectively assess limb volume preoperatively, and lymphedema was defined as a ≥10% relative arm-volume increase arising >3 months postoperatively. Multivariable regression was used to uncover risk factors associated with lymphedema, the Cox proportional hazards model was used to calculate lymphedema incidence, and the semiannual hazard rate of lymphedema was calculated. RESULTS: With a median follow-up of 4 years, the overall estimated 5-year cumulative incidence of lymphedema was 13.7%. Significant factors associated with lymphedema on multivariable analysis were high preoperative body mass index, axillary lymph node dissection (ALND), and regional lymph node radiation (RLNR). Patients receiving ALND with RLNR experienced the highest 5-year rate of lymphedema (31.2%), followed by those receiving ALND without RLNR (24.6%) and sentinel lymph node biopsy with RLNR (12.2%). Overall, the risk of lymphedema peaked between 12 and 30 months postoperatively; however, the time course varied as a function of therapy received. Early-onset lymphedema (<12 months postoperatively) was associated with ALND (HR [hazard ratio], 4.75; P < .0001) but not with RLNR (HR, 1.21; P = .55). In contrast, late-onset lymphedema (>12 months postoperatively) was associated with RLNR (HR, 3.86; P = .0001) and, to a lesser extent, ALND (HR, 1.86; P = .029). The lymphedema risk peaked between 6 and 12 months in the ALND-without-RLNR group, between 18 and 24 months in the ALND-with-RLNR group, and between 36 and 48 months in the group receiving sentinel lymph node biopsy with RLNR. CONCLUSIONS: The time course for lymphedema development depends on the breast cancer treatment received. ALND is associated with early-onset lymphedema, and RLNR is associated with late-onset lymphedema. These results can influence clinical practice to guide lymphedema surveillance strategies and patient education.
引用
- McDuff SGR, Mina AI, Brunelle CL, et al. Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk? Int J Radiat Oncol Biol Phys. 2018. PMID: 30165125. doi:10.1016/j.ijrobp.2018.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。